← Leaderboards
Philip M Bauer
Yale University
$2,060,179
Attributed
$2,060,179
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $525.8K · FY2007–12$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
Funding mix
By agency
NIH$2,060,179 · 3
By mechanism
R01$1,862,259 · 1
R03$151,500 · 1
F32$46,420 · 1
Top collaborators
No co-investigators on record.
Most similar at Yale University
Same institution · by research overlap
- Dieter G Soll$29,619,061
- Joann B Sweasy$35,063,022
- Scott A Strobel$10,998,720
- Sharon Hammes-Schiffer$7,999,004
- Sonia Caprio$32,446,602
Others in their field
Top investigators on “Cell Proliferation”
- John M Lachin · George Washington University$118,921,924
- David M Nathan · Massachusetts Institute Of Technology$118,921,924
- David Heimbrook · Leidos Biomedical Research, Inc.$103,164,048
- Timothy J Eberlein · Washington University$49,931,668
- Deirdre R. Meldrum · University Of Washington$37,202,510
- Robert A Weinberg · Whitehead Institute For Biomedical Res$32,735,166
Research focus
Cell ProliferationMediatingMolecularVascular RemodelingProductionLungPulmonary Artery StructurePulmonary Arterial HypertensionDesignProteinsBaseFunctional DisorderFoundationsFluorescence Resonance Energy TransferEtiologyBiochemicalEndotheliumCyclic GmpCaveolin 1CaveolaeAnabolismCytoprotectionDown-RegulationCarbon Monoxide
Grant awards (9)
The role of innate immunity in idiopathic pulmonary arterial hypertension$75,750
R03 · FY2012 · HL · contact PI
Role of Caveolin-1 and eNOS in Mediating the Therapeutic Effects of CO in PAH.$334,125
R01 · FY2011 · HL · contact PI
Utilization of PHBI resources to study the role of Innate Immunity in Idiopathic$75,750
R03 · FY2011 · HL · contact PI
Role of Caveolin-1 and eNOS in Mediating the Therapeutic Effects of CO in PAH.$334,125
R01 · FY2010 · HL · contact PI
Role of Caveolin-1 and eNOS in Mediating the Therapeutic Effects of CO in PAH.$334,125
R01 · FY2009 · HL · contact PI
Role of Caveolin-1 and eNOS in Mediating the Therapeutic Effects of CO in PAH.$191,634
R01 · FY2009 · HL · contact PI
Role of Caveolin-1 and eNOS in Mediating the Therapeutic Effects of CO in PAH.$334,125
R01 · FY2008 · HL · contact PI
Role of Caveolin-1 and eNOS in Mediating the Therapeutic Effects of CO in PAH.$334,125
R01 · FY2007 · HL · contact PI
Endothelial Specific Caveolin-1 Overexpression$46,420
F32 · FY2003 · HL